ReviewF1000Research2018
Treatment of extended-spectrum β-lactamase-producing
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Rapid phenotypic antimicrobial susceptibility testing of Gram-negative bloodstream isolates: clinical evaluation of the LifeScale AST system.BMC microbiology · 2026Article
- Introducing tetracycline as a potential OXA-48 carbapenemase inhibitor: an in silico and in vitro approach.Scientific reports · 2026Article
- Prevalence of extended-spectrum β-lactamase-producing Enterobacterales and carbapenemase-resistant Enterobacterales in British military cohorts.BMJ military health · 2026Article
- Antimicrobial Resistance and Genomic Characterization of anVeterinary sciences · 2025Article
- Extended spectrum beta-lactamase producing Escherichia coli and antimicrobial resistance gene sharing at the interface of human, poultry and environment: results of ESBL tricycle surveillance in Kathmandu, Nepal.One health outlook · 2025Article
- Impact of the COVID-19 pandemic on the consumption of antibiotics and the emergence of AMR: case study in a general hospital.Frontiers in public health · 2025Article
- Therapeutic Phage Candidates for Targeting Prevalent Sequence Types of Carbapenem-ResistantFoodborne pathogens and disease · 2024Article
- Antibiotic susceptibility patterns and trends of the gram-negative bacteria isolated from the patients in the emergency departments in China: results of SMART 2016-2019.BMC infectious diseases · 2024Article
- Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2024Article
- General Overview ofBiology · 2024Review
- Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2024Review
- Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities.Biomedicines · 2023Review
- Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Can precision antibiotic prescribing help prevent the spread of carbapenem-resistant organisms in the hospital setting?JAC-antimicrobial resistance · 2023Review
- Article
- Detection of Inflammatory Biomarkers Among Patients with Sepsis of Gram-Negative Bacteria: A Cross-Sectional Study.International journal of general medicine · 2023Article
- Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori.PloS one · 2023Article
- Phenotypic characterization and epidemiology of extended-spectrumFrontiers in public health · 2023Article
- Comparative Evaluation of Three Phenotypic Tests-Carba NP, Modified Carba NP and Rapidec Carba NP Test for Rapid Detection of Carbapenem Resistance in Blood Culture Isolates ofThe Malaysian journal of medical sciences : MJMS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of extended-spectrum β-lactamase (ESBL)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.